ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results

WALTHAM, Mass.--(Business Wire)--
ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on
Thursday, August 6, 2009 to discuss the Company`s financial results for the
three-month period and fiscal year ended June 30, 2009. Management also will
provide an update on the Company.

To access the live call by phone, dial 913-981-4900. No passcode is required.
The call also may be accessed through the Investor Information section of the
Company`s website, www.immunogen.com. Following the live webcast, a replay of
the call will be available at the same location through August 13, 2009.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in
cancer biology, monoclonal antibodies and the creation and linkage of potent
cancer-cell killing agents (CKAs) to such antibodies. The Company`s proprietary
Targeted Antibody PayloadTM (TAP) technology consists of ImmunoGen`s highly
potent CKAs, which have been designed specifically for delivery by antibodies to
cancer cells, and the Company`s engineered linkers, which direct the activation
of the CKA inside a cancer cell. Compounds utilizing the TAP technology are in
clinical testing through ImmunoGen`s own programs and its collaborations with
Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen
Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in
Phase III testing being conducted by Genentech and Roche. Other ImmunoGen
collaborative partners include Bayer HealthCare and Amgen.

ImmunoGen, Inc.
Carol Hausner, Executive Director, Investor Relations and Corporate
Communications, 781-895-0600
info@immunogen.com

Copyright Business Wire 2009